Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer

NCT03099499 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT03099499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03099499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
June 8, 2017
Completion date
September 9, 2020
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer